Hepatotoxicity associated with statins.
Bensu Karahalil1, Emine Hare1, Göksel Koç1
11Toxicology Department, Faculty of Pharmacy, Gazi University Ankara, Ankara, Turkey.
Arhiv Za Higijenu Rada I Toksikologiju
|January 17, 2018
Summary
Statins are generally safe, but rare liver injury (DILI) can occur. This review compiles studies on statin-associated hepatotoxicity, highlighting the need for further research into these adverse effects.
Area of Science:
- Pharmacology
- Hepatology
- Drug Safety
Background:
- Statins are widely used cholesterol-lowering drugs, generally considered safe at prescribed doses.
- Clinical trials may not fully capture rare adverse effects like idiosyncratic drug-induced liver injury (DILI).
- Factors such as drug-drug interactions and genetic variations can increase the risk of statin-associated toxicity.
Purpose of the Study:
- To review and synthesize existing literature on statin-associated hepatotoxicity.
- To provide an overview of published studies concerning liver injury caused by statins.
- To discuss the current state of research on statin-induced liver damage.
Main Methods:
- Comprehensive literature search for studies on statin hepatotoxicity.
- Compilation and analysis of existing research data.
- Focus on hepatotoxicity, excluding rhabdomyolysis.
Main Results:
- Hepatotoxicity and rhabdomyolysis are reported adverse effects of statin therapy.
- Existing research has explored mechanisms of statin-induced toxicity.
- This review specifically compiles studies on liver injury, not muscle damage.
Conclusions:
- Research on statin-associated hepatotoxicity is ongoing and essential.
- Understanding the full spectrum of statin adverse effects requires continued investigation.
- Further studies are necessary to fully elucidate the risks of statin-induced liver injury.
